Amedisys (AMED) Tops Q1 EPS by 11c; Offers FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amedisys Reports First Quarter 2022 Financial Results and Reaffirms 2022 Guidance
April 27, 2022 4:05 PM EDTBATON ROUGE, La., April 27, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2022.
Three-Month Periods Ended March 31, 2022 and 2021
Net service revenue increased $8.2Â million to $545.3Â million compared to $537.1Â million in 2021.Net income attributable to Amedisys, Inc. of $31.7Â million compared to $49.9Â million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.97 compared to $1.50 in 2021.Adjusted Quarterly Results*
Adjusted EBITDA of $66.3Â million compared to $78.6Â million in 2021.Adjusted net income attributable to Amedisys, Inc. of $40.1Â million compared to $51.1Â million in... More